An FDA advisory panel has voted to narrowly reject the compounding of tirzepatide while narrowly backing the compounding of semaglutide and another GLP-1 drug. This decision comes as the FDA faces political pressure from the Trump administration and Robert F. Kennedy Jr. to increase access to these weight-loss medications. The votes reflect a contentious debate between FDA staff warning about safety risks and peptide enthusiasts advocating for broader availability.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.